Therefore, individual PKC isoforms were explored as potential targets in several animal models of metabolic diseases, and some preliminary preclinical studies have identified individual PKC isoforms as potential targets for treating metabolic diseases [55,56,240,271]. Here, PRRT2 is linked to metabolic disease.